Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, develops prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, designed to release clinically effective drugs only when exposed to specific physiological conditions; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology. The company's lead product candidate is PF614, a TAAP oxycodone prodrug candidate for the treatment of severe or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat for overdose protection. It is also developing PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for attention deficit hyperactivity disorder; and PF9001 to treat opioid use disorder. Further, It develops neuroplastogenic therapies and psychedelic-derived molecules for severe chronic pain, particularly complex regional pain syndrome (CRPS). Ensysce Biosciences, Inc. was founded in 2003 and is based in La Jolla, California.…
Ensysce Biosciences Announces Participation in Upcoming Investor Conferences
Ensysce Biosciences (NASDAQ: ENSC) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 8 employees.
The shares were at 0.3600 USD on 20 November 2026, down 82.5% over 52 weeks. Its 52-week range is 0.2300 USD to 2.170 USD: the price is 83.4% below the high and 56.5% above the low.
Its market capitalisation is 7.00M USD.
Ensysce Biosciences reports return on equity of -316.6%, an operating margin of -281.3% and revenue down 15.1% year over year.
It holds more cash than debt, a net cash position of 479.86K USD. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health.